Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
TauTona Group is a vertically-integrated operational fund founded in 2010 by Geoffrey C. Gurtner, MD, and Michael Longaker, MD, both professors from the Stanford School of Medicine. The firm is headquartered in Redwood City, California, and focuses on creating, investing in, and developing solutions in medtech, biotech, and regenerative medicine. Their mission is to address unmet clinical needs in healthcare through innovative technologies and sustainable investment practices.
Since its inception, TauTona has established itself as a significant player in the healthcare investment space, emphasizing a sustainable investment model that supports the entire lifecycle of product development. This includes ideation, design, testing, and commercialization, allowing them to effectively de-risk projects. The firm has developed a notable portfolio of medical technologies and has a strong commitment to improving healthcare outcomes while reducing costs.
As of now, TauTona Group operates with a focus on pre-seed, seed, and Series A stages, with a global investment strategy that includes the United States. Their approach combines clinical insights with shared R&D resources, facilitating faster and more efficient commercialization of medical technologies.
TauTona Group invests in and develops innovative medical technologies aimed at improving healthcare outcomes while reducing costs. Their investment strategy encompasses a wide range of stages, including pre-seed, seed, Series A, and extending to Series B and beyond. The firm primarily focuses on sectors such as biotech and medical devices, with a particular emphasis on addressing unmet clinical needs in healthcare.
The organization employs a sustainable investment model that supports the evaluation, design, testing, and development of disruptive ideas. This model allows TauTona to bypass traditional venture capital overhead by directing funds into product development and utilizing shared resources across multiple portfolio technologies. Their investment thesis highlights the importance of targeting smaller healthcare markets that are often overlooked by larger VC funds, ensuring that innovative solutions can reach commercialization more effectively.
TauTona Group has developed a range of notable products that exemplify their commitment to innovation in medical technology. Key products include:
In addition to these current innovations, TauTona has a history of successful exits, including:
Other products in their pipeline include the Theris Medical Patch and various medical devices aimed at enhancing surgical procedures and patient care.
Geoffrey C. Gurtner, MD - Co-Founder & Managing Partner. Dr. Gurtner has a background in clinical insight and medical-device innovation, leveraging his experience as a Stanford-associated physician and researcher.
Michael Longaker, MD - Co-Founder and General Partner. Dr. Longaker specializes in bioengineering and regenerative medicine, drawing on his extensive research background at Stanford University.
Mike Blanchette - Chief Operating Officer. Blanchette leads operations within TauTona's R&D team, ensuring efficient project management and resource allocation.
Kellen Chen - Head of Research. Chen oversees research initiatives within TauTona's development pipeline, focusing on advancing innovative medical technologies.
Susan Hale - Head of Quality and Regulatory. Hale supports quality assurance and regulatory compliance efforts, critical for successful product development in the medical field.
Marta Bulaich - Marketing Development. Bulaich is responsible for commercialization and market development strategies, helping to position TauTona's products effectively in the marketplace.
To pitch TauTona Group, founders should utilize the contact form available at tautonagroup.com/contact.php or send an email to info@tautonagroup.com. The firm maintains an open pitch policy, allowing for rolling applications.
When preparing a pitch deck, it is important to include a clear overview of the technology, the clinical need it addresses, and the potential market size. Founders should also outline their development timeline and any preliminary results or data that support their claims. While specific response times are not disclosed, founders can expect a thorough review of their submissions.
In recent months, TauTona Group has continued to advance its portfolio of medical technologies. Notable products currently in development include the Pneumoperitoneum Assist Device (TPAD), BioBolt Surgical Stapler, and TauTona Wound Dressing (TWD). These innovations reflect the firm's commitment to addressing unmet clinical needs in healthcare.
Additionally, TauTona Group has successfully exited two notable products: Thread Tech, which was acquired by Allergan, and the Tissue Injector, acquired by LifeCell. These exits demonstrate the firm's ability to develop commercially viable medical technologies that attract significant interest from larger healthcare companies.
What are TauTona Group's investment criteria?
TauTona Group focuses on innovative medical technologies that address unmet clinical needs, particularly in smaller healthcare markets. They invest across various stages, from pre-seed to Series C and beyond, emphasizing a sustainable investment model.
How can I pitch to TauTona Group?
Founders can pitch to TauTona Group by visiting their contact page at tautonagroup.com/contact.php or by emailing info@tautonagroup.com. They maintain an open pitch policy with a rolling application cycle.
What makes TauTona Group different from other VCs?
TauTona Group operates as a vertically-integrated operational fund, providing not just capital but also clinical insights, shared R&D resources, and a de-risked development process. This model allows for faster commercialization of medical technologies compared to traditional VC approaches.
What is the geographic focus of TauTona Group?
TauTona Group has a global investment strategy, with a primary focus on the United States. They target healthcare markets worldwide, particularly those that are underserved.
What is the typical check size for investments?
While specific check sizes are not disclosed, TauTona Group invests across various stages, indicating flexibility in their funding approach based on the needs of the startup.
What kind of support can portfolio companies expect?
Portfolio companies benefit from TauTona Group's operational model, which includes access to clinical insights, R&D resources, and assistance throughout the product development lifecycle, enhancing their chances of successful commercialization.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.